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Abstract
A 15 years old child with Lyme borreliosis was treated with me-
peridine via a patient controlled analgesia (PCA) pump for pain 
management. He had no history of seizure and had normal hepatic 
and renal functions. At the 7th hour of meperidine PCA delivery, 
generalized tonic-clonic seizure was developed and successfully 
suppressed with antiepileptics and no neurologic sequel was oc-
curred. The total meperidine consumption in the patient was quite 
lower  than  the  recommended  doses  with  PCA. Although  Lyme 
disease might also cause seizure activities, the timing of the sei-
zures was related with the accumulation of normeperidine which 
is the main metabolite of meperidine with central nervous system 
stimulant effect. The meperidine pain management on patients with 
Lyme syndrome should be reconsidered to avoid undesired effects.
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Introduction
Lyme borreliosis is a tick-borne spirochetal infection with 
Borrelia burgdorferi which affects the skin, joints, heart and 
nervous system. Acute transverse myelitis, meningoradicu-
litis with pain, paraesthesia, and cranial nerve palsies and 
seizures with regional leptomeningeal enhancement are the 
leading symptoms of children with neuroborreliosis [1]. Epi-
leptic seizures are poorly understood manifestations of this 
demyelinating disease and cerebral vasculitis that are dis-
closed on MRI (Magnetic resonance imaging) as ischemic 
foci which are substantiated for seizures in Lyme disease [2].
The neurological symptoms develop in 10 - 20% of chil-
dren with borreliosis, and epileptic seizures in these children 
have only been described sporadically [3]. But it is well-
known that the predisposition to seizure activity increases 
in patients with borreliosis when accompanied symptoms of 
central nervous system dysfunction occur. Besides, medical 
therapies with different epileptogenic potentials like meperi-
dine, sevoflurane, clozapine, phenotiazines and cyclosporine 
can  increase  central  nervous  system  excitability  by  their 
activated metabolites or contribute to reducing the seizure 
threshold [4]. Therefore, the routine use of these drugs in 
patients under the risk of epileptic seizures should be recon-
sidered to prevent the complicity of differential diagnosis 
during the essentially expected seizure attacks. 
In this report, we described the case of generalized ton-
ic-clonic  seizures  induced  by  patient  controlled  analgesia 
(PCA) with meperidine for pain management due to tonic 
spasms secondary to demyelination in a 15 year-old patient 
with Lyme syndrome who had no seizures during the initial 
examinations.
 
Case Report
A 15 years old patient (BW: 55 kg) was diagnosed as Lyme 
disease according to serological studies for B. burgdorferi 
(ELISA, Western blot) which were positive for IgG in serum 
and CSF. His initial symptoms were aching pain, especially 
in the legs with proximal weakness of the lower extremities. 
He had no previous history of seizure and had normal hepatic 
and renal functions. The patient was hospitalized for antibio-
therapy and control of diffuse muscle pains and treated with 
ceftriaxon and paracetamol. The patient was referred to the 
pain management service for appropriate medical treatment 
as his NRS (numeric rating scale) score was still 9.
The medical pain therapy was ordered with meperidine 
PCA and the pump was set to inject 5 mg/hour basal infusion, 
5 mg bolus with a lockout time of 30 minutes. Following the 
first 30 minutes with initial bolus injection, the NRS score 
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was decreased to 3 and at the 7th hour of the administration 
he was found in his bed having a generalized tonic-clonic 
seizure and the attack was successfully suppressed by 0.1 
mg/kg midazolam and 10 mg/kg phenytoin. Since remaining 
meperidine, the patient had no further seizures, but because 
of the suspicion that Lyme syndrome could be responsible 
for triggering seizures, the pain therapy with meperidine was 
continued. 
The epileptic attack was repeated 3 hours after the first 
generalized tonic-clonic seizure and was again successfully 
suppressed by phenytoin monotherapy, and meperidine infu-
sion was terminated temporarily. Since remaining off me-
peridine, the patient had experienced no further seizures and 
regained consciousness without focal neurologic findings, 
and meperidine therapy was terminated definitely. The pain 
therapy was re-arranged with paracetamol (500 mg, infu-
sion) and 15 drops of tramadol daily.
Discussion
  
Lyme borreliosis is a multisystem disease associated with 
cranial nerve palsies, peripheral and cranial radiculopaties, 
aseptic menengitidis, encephalatic symptoms, seizures and 
demyelinating polyneuropathy. Vasculitis is thought to be 
the  primary  pathophysiological  mechanism  for  focal  ce-
rebral lesions and its clinical reflection occurs as seizures. 
There is also raising suspicion that borreliosis itself could be 
responsible for triggering seizures [1]. 
The clinical manifestations of Lyme borreliosis differ 
from patient to patient, and most symptoms occur rarely. 
Painful  meningoradiculitis  and  paraesthesia  is  one  of  the 
rarely occurred symptoms. The treatment modalities for pain 
especially in pediatric patients sustain special practice, and 
the main target in pain management has to contain both suc-
cessful medical choices and any adverse effects.  
Meperidine, through the medical choices, is one of the 
most commonly prescribed opioid analgesic with its’ high 
central nervous system depressant effects. Unlike this prop-
erty, its main metabolite, normeperidine, is a central nervous 
system excitatory agent. Despite the fact that normeperidine 
has half the analgesic potency, it has twice neurotoxic effect 
of meperidine, and its accumulation can lead to symptoms of 
central nervous system toxicity such as nervousness, hyper-
reflexia, tremors, myoclonus, and generalized seizures with 
repeated use. These effects are nonopioid in nature and they 
can not be reversed by opioid antagonist administration [5].
The identified risk factors for the development of meper-
idine-related seizures include renal failure, high meperidine 
dosages, and co-administration of hepatic enzyme inducing 
medications  or  phenothiazines.  However,  healthy  patients 
with normal renal function might also manifest to seizure 
activity due to rapid accumulation of normeperidine or might 
contribute by reducing the seizure threshold in specified dis-
ease with demyalinization [6, 7].
Through the previous reports, meperidine related sei-
zures  associated  with  PCA  pumps  in  healthy  adolescents 
and young patients, with normal renal function and with-
out the history of epilepsy, have been reported. In one of 
these healthy adolescents, a total of 1110 mg meperidine 
was received for postoperative pain control during the first 
23 hours. Thirty minute after discontinuation of the PCA, 
the  patient  was  noted  to  exhibit  tonic-clonic  movements. 
The  serum  meperidine  concentration  was  measured  1418 
ng.ml-1 while the therapeutic serum meperidine ranges were 
between 200 and 800 ng.ml-1. One month later, the patient 
received again meperidine via PCA, but this time the patient 
received only a total of 491 mg meperidine without any sign 
of central nervous system excitation [8]. This patient expe-
rienced a seizure after standard therapeutic doses of meperi-
dine PCA and had no previously identified risk factors for 
the development of meperidine induced seizures. Our patient 
received a total of 110 mg meperidine within 7 hours which 
was approximately the tenth amount of the previously repre-
sented adolescent’s dose, and that was also quite lower than 
the recommended doses with PCA but it was sufficient for 
generalized tonic-clonic seizure occurrence. 
Seizures in an Alzheimer’s disease patient as a compli-
cation of colonoscopy premedication with meperidine have 
also been reported and attributed to the neuronal changes 
which occur during the progress of the illness as it was ex-
perienced in our patient [7]. The neural changes which oc-
cur in Lyme syndrome can themselves also predispose to 
seizures in this kind of rarely experienced cases. Although 
the underlying pathology and the changes due to the disease 
itself might also be supposed to the causes of seizures activ-
ity in our patient, the timing of the seizures was suspended 
from this potential possibility and we thought that the main 
cause of the seizures was probably due to the accumulation 
of normeperidine and its central nervous system stimulant 
effect. 
In conclusion, this is the first case report of meperidine 
acting as the precipitating factor for generalized tonic-clonic 
seizures in a child with Lyme disease. We recommend avoid-
ance of meperidine for pain management on patients with 
Lyme syndrome and on any patient with a condition that 
predisposes to seizure, to not to complicate the differential 
diagnosis and we suggest the use of alternative opioids and 
adjuvants for the pain management.    
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